top of page
Supported projects
The cluster provides access to the best oncology skills, tools, and services for the most promising projects led by organizations of varying sizes and maturity. The PSCC takes a selective approach, focusing its resources where they can have the greatest impact. We evaluate projects at different stages of maturity based on the quality of their team, scientific strength, development opportunities, and their alignment with the cluster's objectives. Our rigorous selection process involves an independent evaluation committee composed of experienced scientists and industry leaders.
Projects filters
Abbelight's project to develop a liquid biopsy diagnostic technology combining super-resolution microscopy, extracellular vesicles and artificial intelligence. This approach improves the detection and analysis of circulating biomarkers, offering greater precision for the early diagnosis and monitoring of diseases, particularly in oncology. By integrating these advances, the solution optimises precision medicine and opens up new prospects for more targeted and effective treatments.
France
Île-de-France
Medtech
TechBio
Medtech - Development
Abbelight
Abcely is developing an innovative immunotherapy based on orally administered IgA monoclonal antibodies, targeting cancers of the digestive mucosa and endometriosis. Thanks to their polymeric structure, IgA antibodies are more avid for their target and recruit neutrophils more effectively. A unique platform for the identification, optimisation and production of these antibodies, offering an alternative to intravenous or subcutaneous IgG treatments.
France
Pays de la Loire
Biotech
Immunotherapy
Biotech - Pre-IND/Pre-CTA
Lauréat
iLAB
Abcely
Specializes in the discovery of biomarkers and the development of innovative medical diagnostics for precision medicine. In particular, it is developing GEMCITEST®, a blood test that predicts patient response to gemcitabine as a first-line treatment.
France
Occitanie
Medtech
DM/DiV
Medtech - Approval
Acobiom
Is developing a portfolio of first-in-class peptides targeting the tumour microenvironment. Its most advanced programme, AP-01, is a cyclic peptide inhibiting TSP-1, a ligand of the CD47 receptor, in various tumour indications with a high medical need. Other promising programmes targeting the extracellular matrix are also in development.
France
Grand Est
Biotech
Targeted therapy
Biotech - Pre-IND/Pre-CTA
Lauréat
iLAB, iNov, EIC laureate
Apmonia Therapeutics
Based on the discovery of the role of the transmembrane receptor Tmem176b in the regulation of tumour inflammation. It is developing compounds targeting this receptor to reactivate inflammation and boost anti-tumour activity, particularly in melanoma, colorectal cancer and chronic lymphatic leukaemia.
Argentina
Santa Fe
Biotech
Immunotherapy
Biotech - Lead optimization
ARDAN Pharma
Develops drugs targeting the mutated DNA that causes serious diseases, with a particular focus on paediatric tumours. Using its proprietary MyGenera™ platform, the company rapidly identifies and designs ultra-specific therapies tailored to each patient. This revolutionary approach opens up new prospects for treating hitherto incurable pathologies.
Italy
Bologna
Biotech
Cell & Gene therapy
Biotech - Pre-IND/Pre-CTA
Biogenera
Specializing in the development of innovative cell therapies - chimeric antigen receptor T cells (CAR-T), T cell receptor T cells (TCR-T) and tumor-infiltrating lymphocytes (TIL) - for the treatment of cancer.
Singapore
Singapore
Biotech
Cell & Gene therapy
Biotech - Phase 2
BioSyngen
A biotech developing first-in-class oral small molecule targeting BiP, a key protein involved in cancer cells survival and associated with poor prognosis when overexpressed in tumors and in plasma of patients. The start-up targets BIP+ patients through precision medicine approach.
France
Grand Est
Biotech
Targeted therapy
Pre-IND/Pre-CTA
Biper Therapeutics
Blue Bees is developing first-in-class immunotherapies based on a breakthrough technology exploiting dual targeting of cell receptors coupled to heparan sulphate proteoglycans (HSPGs). This innovative approach aims to boost the anti-tumour immune response and open up new therapeutic prospects.
France
Île-de-France
Biotech
Immunotherapy
Biotech - Pre-IND/Pre-CTA
Blue Bees Therapeutics
Develops next-generation allogeneic immunotherapies to prevent cancer recurrence, the main challenge in solid tumours. Using its patented technology platform, the company designs first-in-class therapeutic vaccines targeting tumour antigens and educating the immune system to overcome tumour resistance. Its lead candidate, a proteomic immunotherapy, targets colorectal cancer, the second most common cause of cancer deaths worldwide.
France
Auvergne-Rhône-Alpes
Biotech
Immunotherapy
Biotech - Pre-IND/Pre-CTA
Lauréat
iLAB
Brenus Pharma
A preclinical stage biotech developing a pipeline of precision immunotherapies for severe and aggressive diseases based on a fully integrated adaptive CAR-T platform plug-and-play technology.
France
Bourgogne Franche Comté
Biotech
Cell & Gene therapy
Biotech - Pre-IND/Pre-CTA
Lauréat
iLAB
Carla Biotherapeutics
Aims to develop a platform for the genetic engineering of autologous monocytes to boost anti-tumour immunity, with an approach aimed at designing personalized cell therapies and enabling the rapid and effective reinfusion of modified monocytes to fight cancer.
France
Île-de-France
Biotech
Cell & Gene therapy
Biotech - Discovery
CedraTherapeutics
Is developing a real-time surgical guidance technology combining laser, mass spectrometry and artificial intelligence. Its innovative system enables precise identification of tumour tissue and surgical margins, optimising tumour removal while preserving healthy tissue. The aim of this approach is to reduce the risk of relapse and improve the outcome of oncology operations.
France
Hauts de France
Medtech
DM
Medtech - Development
Lauréat
iLAB
Celeos
Focused on the manufacturing of breakthrough cell therapies. Their bioreactor with unique properties (controlled shear forces, homogeneity, easy scale-up, etc.) meets the challenges of expanding induced pluripotent stem (iPS) cells.
France
Provence-Alpes-Côte d'Azur
Medtech
TechBio
Medtech - Laboratory PoC
Cellura
Cherry Biotech markets a technological platform integrating cellular engineering, microfluidics, artificial intelligence and advanced imaging to recreate 3D human models (organs on a chip). Its aim is to anticipate the impact of treatments on the body, particularly for orphan diseases, cancer and bacterial resistance. Its patented CUBIX technology makes it possible to grow complex, vascularized tissue models, offering an ethical and innovative alternative to animal testing, while integrating into current industrial workflows.
France
Île-de-France
Medtech
TechBio
Medtech – Market
Lauréat
iLAB, EIC laureate
Cherry Biotech
Is developing a therapeutic target discovery platform based on a proprietary clinical and multiomics database of patients who have survived aggressive cancers. By combining comparative multiomics analyses with artificial intelligence and computational modelling, Cure51 identifies unique biological signatures to design new targeted therapies and open up new perspectives in oncology.
France
Île-de-France
Medtech
TechBio
Medtech - Development
Lauréat
iLAB
Cure51
Is developing an AI-based tool to predict patient response to immunotherapies and optimise therapeutic decisions. By combining genomics, imaging and clinical data, its platform offers personalized recommendations, improving the effectiveness of treatments while reducing adverse effects and costs.
UK
Londres
Medtech
DM/DiV
Medtech - Development
Curenetics
A diagnostics platform company licensing patented RNA chemical modifications as biomarker signatures for early cancer detection. Its multiplex technology combines mass spectrometry and machine learning to deliver scalable, low-input solutions for IVD partners.
France
Occitanie
Medtech
TechBio
Medtech - Development
.png)
Cyberna
Develops a SaaS platform combining generative AI and multi-omics data to create digital twins of cells, accelerating cellular engineering and drug discovery. Using deep learning algorithms, this technology enables in silico simulations to identify new therapeutic targets. A current project focuses on brain stem infiltrating glioma (BSIG), a rare paediatric cancer.
France
Île-de-France
Medtech
TechBio
Medtech - Development
DeepLife
Has patented a diagnostic technology based on multi-dosing of circulating miRNAs by electrochemistry in microfluidics, combining magnetic hyperthermia and electrochemical detection for rapid, sensitive and multiplexed analysis, facilitating early cancer detection with increased accuracy and reduced cost.
France
Île-de-France
Medtech
DM/DiV
Medtech - Development
e-miRgency
A spin-off from the Vaccine Research Institute, EnnoDC is a clinical-stage immunotherapy company pioneering antibody-mediated vaccines (AMVs) for cancers and infectious diseases.
By precisely delivering the antigen of interest to dendritic cells, AMVs maximize CD8, CD4 T, and B cell responses. With no collateral toxicity and fully scalable, its candidates fit into a unique plug-and-play platform, ensuring targeted and long-lasting immunity.A spin-off from the Vaccine Research Institute, EnnoDC is a clinical-stage immunotherapy company pioneering antibody-mediated vaccines (AMVs) against cancers and infectious diseases. By precisely delivering the antigen of interest to dendritic cells, AMVs maximise CD8, CD4 T and B responses. With no collateral toxicity and fully scalable, these candidates can be integrated into a unique plug & play platform, guaranteeing targeted, long-lasting immunity.
France
Île-de-France
Biotech
Immunotherapy
Biotech - Phase 1/2a
EnnoDC
Designs immunotherapies based on the identification of unconventional tumour antigens derived from human endogenous retroviruses (HERVs). Using an approach combining artificial intelligence, proteomics and immunology, it is developing therapeutic vaccines and cell-based therapies to target cold tumours. Its lead candidate is a universal vaccine against triple-negative breast cancer and ovarian cancer.
France
Auvergne-Rhône-Alpes
Biotech
Vaccine
Biotech - Pre-IND/Pre-CTA
Lauréat
iLAB, EIC laureate
ErVimmune
Is developing the Oncobax® AK biotherapy, which uses immunogenic commensal bacteria to enhance the efficacy of immune checkpoint inhibitors. This approach is based on the modulation of intestinal microbiota to improve the response to immunotherapies in the treatment of kidney cancer and non-small cell lung cancer.
France
Île-de-France
Biotech
Microbial-based therapy
Biotech - Phase 1
EverImmune
Designs highly sensitive technologies for the analysis of extracellular vesicles, opening up new perspectives in liquid biopsy. Its diagnostic platforms enable the early detection of cancer, particularly ovarian cancer, by identifying protein markers with unrivalled precision. This innovative approach improves screening, tumour monitoring and anticipation of relapse.
France
Île-de-France
Medtech
DM/DiV
Medtech - Development
Exosome Analytics
Develops a simple, effective blood test for the early detection of multiple types of cancer. By exploiting exosome biology, this liquid biopsy technology enables tumours to be identified at a very early stage, even in asymptomatic patients. The aim is to make this detection available worldwide, using standard laboratory techniques and at an affordable cost.
Italie
Cardiff
Medtech
DM/DiV
Medtech - Development
Exosomics
Develops, produces, and markets innovative diagnostic tests based on next-generation sequencing to better characterize non-Hodgkin lymphomas and sarcomas. These patented tests offer rapid and reliable diagnoses without requiring additional equipment, facilitating their adoption in routine clinical practice and optimizing patient care.
France
Normandie
Medtech
DM/DiV
Medtech – Market
Genexpath
Is developing a microwave ablation platform incorporating a flexible catheter equipped with a temperature sensor for real-time monitoring of tissue ablation. This minimally invasive technology offers surgeons a safer and more precise solution for the early treatment of lung cancer, by directly targeting lesions without recourse to major surgery.
France
Île-de-France
Medtech
DM
Medtech - Development
HEPTA Medical
A start-up develops an oral drug HPX-612 targeting intestinal innate immunity and treat metastatic and agressive pediatric cancers.
France
Normandie
Biotech
Immunotherapy
Biotech - Pre-IND/Pre-CTA
HIPPOXIS
Hephaistos is developing innate immunity modulators capable of transforming immuno-resistant ‘cold’ tumours into ‘hot’ tumours by modifying their micro-tumour environment. The company has obtained preclinical proof-of-concept for the first systemic TLR4 activator with efficacy against primary tumours and metastases, alone and in combination. The HEPHA-440 drug candidate has received orphan drug designation for the treatment of osteosarcoma and is expected to enter the clinic by 2027.
France
Île-de-France
Biotech
Immunotherapy
Biotech - Pre-IND/Pre-CTA
Lauréat
iLAB, iNov, EIC laureate, RHU
Hephaistos Pharma
Developing a patented smart hydrogel combining an immunological adjuvant and a cytokine to treat advanced and metastatic “cold” tumours.
France
Île-de-France
Biotech
Immunotherapy
Pre-IND/Pre-CTA
IMISCA Therapeutics
Has designed a robot dedicated to flexible interventional endoscopy for minimally invasive operations inside the patient. By bringing surgical instruments to the end of the endoscope, this technology democratizes complex gastroenterology operations.
France
Normandie
Medtech
DM
Medtech - Development
INEN Robotics
Building on major scientific advances in the regulation of endoplasmic reticulum stress, this future start-up aims to propose an innovative drug candidate to meet major medical needs in glioblastoma and brain metastases.
Suède
Suède
Biotech
Targeted therapy
Biotech - Lead optimization
IREX
Aims to develop imaging biomarker signatures to predict prognosis and response to immunotherapy. By combining radiomics and artificial intelligence, this future start-up aims to transform the analysis of medical images into a powerful predictive tool, enabling greater personalisation of oncology treatments.
France
Île-de-France
Medtech
DM
Medtech - Laboratory PoC
IRIS
Specializing in the discovery of new drug candidates using its in silico drug design technology platforms, InFocus is developing a pipeline of small molecules capable of modulating the translation of oncogenic mRNAs. Its drug candidates, with excellent brain penetration properties, target central nervous system cancers such as glioblastoma and brain metastases, opening up new prospects for treating previously inaccessible targets.
France
Île-de-France
Biotech
Targeted therapy
Biotech - Lead optimization
InFocus
Clinical-stage biotech company developing an ADC targeting the transferrin receptor and coupled with MMAE, with a first clinical trial in hematological cancers.
France
Île-de-France
Biotech
Targeted therapy
Biotech - Phase 1b
Inatherys
A child-first approach to cancer immunotherapy through next-generation cancer gene therapies harnessing the power of children’s immune systems.Awarded 1st prize at Hack4Hope 2025.
UK
Londres
Biotech
Other
Lead optimization
Kindling Bio
Commercialises an intelligent and intuitive search platform for oncology clinical trials, facilitating patient access to new therapeutic options and helping doctors to quickly identify suitable studies thanks to AI.
France
Île-de-France
Medtech
e-health
Medtech – Market
Klineo
An AI-powered oncology company developing a universal digital twin in oncology to predict new therapeutic indications through AI-driven mutational pathway analysis and multi-omics stratification.
France
Île-de-France
Medtech
Medtech - Medical Device
Lafame
Has developed an innovative mammography technology from a CNRS laboratory, enabling early detection of breast cancer by visualizing small masses in dense tissue.
France
Nouvelle Aquitaine
Medtech
DM
Medtech - Laboratory PoC
LetSee Imaging
MS Insights, a company specializing in genomics and bioinformatics, is developing innovative diagnostic solutions for the analysis of microsatellite instability (MSI), a key biomarker in oncology. Using tools based on high-throughput sequencing (NGS) data, the company provides valuable information on microsatellite variations, optimising diagnosis and therapeutic guidance, particularly for immune checkpoint inhibitors. Its flagship product, MSIcare, aims to become a benchmark in diagnosis, prognosis and theranostics.
France
Auvergne-Rhône-Alpes
Medtech
DM/DiV
Medtech - Development
Lauréat
iLAB
MSInsight
Is developing a new generation of immunoconjugates targeting CD56+ cancers. Its first candidate is an ADC, designed to deliver a cytotoxic load directly to tumour cells, with a focus on small cell lung cancer and Merkel cell carcinoma.
France
Centre Val de Loire
Biotech
Targeted therapy
Biotech - Lead optimization
McSAF Inside Oncology
A diagnostics company developing real-time liquid biopsy tests based on proprietary DNA methylation signatures to monitor cancer evolution and treatment response.
France
Île-de-France
Medtech
DM/DiV
Medtech - Liquid Biopsy
Methys Dx
Diagnostic company which offers simple and effective blood biological tests to evaluate individual radiosensitivity to optimize radiotherapy treatment and thus improve the quality of life of patients.
France
Grand Est
Medtech
DM/DiV
Medtech – Market
.png)
NEOLYS Diagnostic
A start-up developing nanobody-based theranostic solutions targeting newly identified pathobionts, known to be associated with cancers
France
Normandie
Biotech
Nanobodies
Biotech - Microbial-based therapy
NanoKur
Biotech en phase clinique développant deux modalités de nouvelle génération — des radiopharmaceutiques à l’astate-211 et des anticorps bifonctionnels engageant les cellules NK — pour le carcinome hépatocellulaire et le myélome multiple.
USA
Florida
Biotech
targeted alpha-therapy and bispecific Ab
Biotech - Phase 1b
Naya Therapeutics
Develops functionalized gold nanoparticles to deliver innovative dual therapy for glioblastoma, combining chemotherapy and radiotherapy in a smart nanosphere. This synergistic approach boosts treatment efficacy while reducing side effects, thanks to precise targeting of solid tumorstumours.adiothérapie dans une nanosphère intelligente. Cette approche synergique augmente l’efficacité du traitement tout en réduisant les effets secondaires grâce à un ciblage précis des tumeurs solides.
France
Bourgogne Franche Comté
Biotech
Nanomedecine
Biotech - Lead optimization
ORINOVA
Develops next-generation immunotherapies for the treatment of cancer. Its clinical platform is based on innovative approaches aimed at boosting the anti-tumour immune response and overcoming resistance to current treatments.
France
Île-de-France
Biotech
Immunotherapy
Biotech - Phase 1/2a
Onconex-Remunity Therapeutics
Oncovita is an Institut Pasteur spin-off developing immuno-virotherapies for solid cancers, based on a genetically modified measles vaccine virus. Its lead candidate, MVdeltaC, is an oncolytic virus capable of inducing immunogenic cell death, and has shown promising preclinical results in numerous models, including immunocompetent mice. This virus specifically targets tumour cells overexpressing the CD46 receptor and induces a durable anti-tumour immune response.
France
Île-de-France
Biotech
Immuno virotherapy
Biotech - Pre-IND/Pre-CTA
Oncovita
Leverages single-cell technologies and artificial intelligence to establish high-resolution omic profiles for precision medicine.
France
Île-de-France
Medtech
DM/DiV
Medtech - Development
One Biosciences
Operates a technology platform combining patient tumour avatars with real clinical data and cutting-edge biology. This artificial intelligence-powered approach accelerates the identification of therapeutic targets and the development of treatments, while optimizing the recruitment of responder patients.
France
Île-de-France
Medtech
TechBio
Medtech - Development
Lauréat
iLAB
Orakl Oncology
Develops monoclonal antibodies neutralizing ACBP/DBI, the level of which is very high in various pathologies, notably cancers, and which is responsible for the feedback inhibition of cellular autophagy.
Suisse
Lausanne
Biotech
Targeted therapy
Biotech - Discovery
.png)
Osasuna
Creation of a start-up dedicated to the development of a drug candidate for the treatment of pancreatic cancer, based on the discovery of a new therapeutic target.
France
Provence-Alpes-Côte d'Azur
Biotech
Targeted therapy
Biotech - Discovery
PANCA
Develops innovative peptides as targeted therapies in oncology. Its lead drug candidate, PEP-010, is a pro-apoptotic peptide that has demonstrated anti-tumoranti-tumour efficacy in several preclinical models, as well as good tolerability and encouraging early signals of anti-tumoranti-tumour activity in Phase Ia clinical trials. The Phase Ib trial is currently underway, focusing on platinum-resistant ovarian cancer and pancreatic adenocarcinoma.
France
Île-de-France
Biotech
Targeted therapy
Biotech - Phase 1b
PEP Therapy
Une start-up spécialisée dans les technologies médicales qui développe des tests de dépistage non invasifs basés sur l'analyse d'urine pour les cancers féminins, combinant la détection de biomarqueurs et des algorithmes d'IA pour permettre un diagnostic précoce des cancers du sein, des ovaires, de l'endomètre et du col de l'utérus.
France
Île-de-France
Medtech
DMDIV
Medtech - Development
PeekCell
Pegascy specializes in repositioning oncology compounds that have been discontinued after Phase 1, by exploring their therapeutic potential in various indications. The company is currently developing istiratumab, a bispecific Igfr/Her3 antibody, in Phase 2 for Ewing's sarcoma and endometrial cancer. Following the success of PegaOne, which will be sold to Centessa in 2021, PEGASCY is preparing the launch of PegaTwo, targeting pediatric and female cancers.
France
Île-de-France
Biotech
Targeted therapy
Biotech - Phase 2
Pegascy
Develops first-in-class peptides that have demonstrated preclinical efficacy in several solid and liquid cancers, notably chronic lymphocytic leukemia, with no observed toxicity. Thanks to an innovative platform combining biology, chemistry and artificial intelligence, peptides are designed to specifically target CD47, enabling tumour cells to be destroyed while sparing healthy cells.
France
Île-de-France
Biotech
Targeted therapy
Biotech - Lead optimization
Lauréat
iLAB
PepKon
Develops an allogeneic suicide gene therapy (MTI) to treat liver cancer. The therapy uses allogeneic mesenchymal stem cells transfected with a cyclophosphamide-activated suicide gene (CPA), enhancing tumour sensitivity to chemotherapy. The mechanism enables tumour destruction while generating an immune response that prevents tumour recurrence. Proof of concept carried out in vitro and in vivo.
France
Île-de-France
Biotech
Cell & Gene therapy
Biotech - Lead optimization
Persea
Is marketing a new generation of cancer screening tests, particularly for prostate cancer, based on a personalized “in silico” approach. By combining in-vitro biological data with the patient's personal information, these accessible, non-invasive tests enable a more accurate risk assessment and referral to complementary examinations, such as ultrasound, for an early, personalized diagnosis.
France
Grand Est
Medtech
DM/DiV
Medtech – Market
Prostperia
Is marketing a new generation of cancer screening tests, particularly for prostate cancer, based on a personalized “in silico” approach. By combining in-vitro biological data with the patient's personal information, these accessible, non-invasive tests enable a more accurate risk assessment and referral to complementary examinations, such as ultrasound, for an early, personalized diagnosis.
France
Île-de-France
Medtech
TechBio
Medtech - Development
.png)
Quintessence Biotech
Develops an artificial intelligence solution to improve radiological analysis, enabling the detection of tumours, the monitoring of their evolution and the measurement of RECIST criteria. Thanks to a multimodal model, this technology can integrate and analyze different types of data, such as images and text, facilitating access to imaging biomarkers for more accurate diagnoses.
France
Île-de-France
Medtech
DM
Medtech - Development
Lauréat
EIC laureate, iLAB
Raidium
Rainpath uses AI to virtually "stain" biopsy images , helping doctors see tissue details more clearly and make faster, more accurate diagnoses without traditional lab processing.
France
Bretagne
Medtech
DM/DiV
Medtech - Development
.png)
Rainpath
Is developing an innovative platform of biocompatible, biodegradable polysaccharide-based hydrocolloid gels for the controlled subcutaneous release of therapeutic antibodies and ADCs. This approach aims to make biological cancer treatments more accessible by facilitating rapid, convenient subcutaneous administration for patients and hospitals.
France
Grand Est
Biotech
Targeted therapy
Biotech - Lead optimization
Recobia Tx
A biotechnology company developing AI-augmented 3D in vitro culture systems using hydrogel-based microfluidics and proprietary data to improve drug efficacy and safety prediction.
France
Île-de-France
Medtech
Techbio
Medtech - Development
SYNTOPIA
Develops a diagnostic probe for fluorescence-guided surgery, aimed at detecting tumours invisible to the naked eye and preventing relapse of abdominal cancers. Targeting peritoneal metastases from colorectal, gastric, ovarian and pancreatic cancers, this technology enables early and accurate detection of lesions, whether visible during open or minimally invasive surgery, helping to improve surgical outcomes and reduce the risk of recurrence.
France
Occitanie
Biotech
Fluorescent-probe for targeted surgery
Biotech - Lead optimization
See2Cure
Shifting to a new paradigm, Seekyo, a preclinical stage biotech, offers a breakthrough approach for solid tumors in targeting specific functional proteins within the Tumor Micro-Environment : Tumor Activated TherapyTM
France
Nouvelle-Aquitaine
Biotech
Targeted therapy
Biotech - Pre-IND/Pre-CTA
.png)
Seekyo Therapeutics
Develops a targeted antigen delivery system using plant-derived nanoparticles, enabling rapid, cost-effective production. The technology is based on modular particles capable of carrying various active ingredients (proteins, peptides, mRNAs) and specifically targeting immune cells, notably in therapeutic oncology vaccines. This approach optimizes the activation of immune responses against tumours, with simple, human pathogen-free production and high stability for practical use.
France
Grand Est
Biotech
Immunotherapy
Biotech - Discovery
Serendip innovations
A CEA spin-off developing first- and best-in-class anti-GPCR (G-protein-coupled receptors) antibody-drug conjugates (ADCs) with a proprietary cleavable linker technology for solid tumours and haematological malignancies.
France
Centre Val de Loire
Biotech
Immunotherapy
Pre-IND/Pre-CTA
Skymab Biotherapeutics
Markets portable products for liquid biopsy of circulating tumour cells (CTCs), to make this procedure standardized, accessible and used in routine clinical practice. This liquid biopsy approach offers better representativeness of solid tumours by enabling real-time monitoring, while personalizing care. These microfiltration devices isolate CTCs directly from whole blood, without the need for pre-analytical steps, facilitating diagnosis, monitoring and personalized treatment.
France
Occitanie
Medtech
DM/DiV
Medtech – Market
Lauréat
iLAB
SmartCatch
A new biotech which plans to rejunevate the field of immune checkpoint blockade for cancer therapy by exploring next generation checkpoint inhibitors which are relevant to endothelial cell biology and also pursuing canonical checkpoint inhibitors.
USA
Delaware
Biotech
Immunotherapy
Biotech - Discovery
Spice Bio
Start-up proposing therapies that eliminate senescent cells induced by standard cancer treatments.
France
Hauts de France
Biotech
Targeted therapy
Biotech - Lead optimization
Lauréat
iNov
Starkage Therapeutics
Develops first-in-class drug targeting cGAS and using mRNA technology to stimulate innate immunity. By activating the STING pathway, this approach boosts the immune response against cancers and other pathologies, particularly in patients refractory to conventional treatments. Using virus-like particles (VLPs), this technology stimulates cytokine production and boosts immune cell response.
France
Île-de-France
Biotech
Immunotherapy
Biotech - Lead optimization
Lauréat
iLAB
Stimunity
A start-up biotech wich develops bioengineered nanofilaments, a new class of immunotherapies, designed to bind to cancer cells and mark them for immune attack.
Canada
Canada
Biotech
Immunotherapy
pre-IND/ CTA
Tatum Bioscience
Combines the Warburg effect and click chemistry to improve addressing of various anti-tumour molecules (small molecules, SiRNAs, antibodies, etc.) and reduce their side effects. Thanks to the specific uptake by tumour cells of patented modified sugars fitted with chemical hooks, this method enables therapeutic agents to be concentrated locally via a “click” chemical reaction (Nobel Prize 2022) between the cell hooks and the charge carriers.
France
Provence-Alpes-Côte d'Azur
Biotech
Targeted therapy
Biotech - Lead optimization
TheraOnco
Is developing a revolutionary technology using non-invasive focused ultrasound to enhance drug delivery to the brain. By specifically targeting the blood-brain barrier (BBB), this approach makes it possible to cross this protective barrier and deliver therapeutic treatments to targeted areas of the brain, as in the case of primary tumours or brain metastases.
France
Île-de-France
Medtech
DM
Medtech - Development
Lauréat
iLAB
TheraSonic
A first-in-class LCOR (Ligand-dependent corepressor) mRNA therapy designed to enhance the efficacy of cancer immunotherapies in metastatic settings.
Espagne
Espagne
Biotech
Immunotherapy
Lead optimization
VIOLET Pharmaceuticals
Exploits the natural properties of the sortilin protein to develop therapeutic solutions targeting EGFR-positive tumours. Their first innovation is a sortilin-derived peptide designed to treat lung adenocarcinoma.
France
Nouvelle Aquitaine
Biotech
Targeted therapy
Biotech - Lead optimization
Yomi Pharma
Supported projects
Projects filters
Spin-off de l’Institut Curie, Emglev Therapeutics utilise sa plateforme propriétaire unique d'anticorps synthétiques de nouvelle génération pour découvrir et développer des immunothérapies transformatrices afin de répondre aux besoins médicaux non satisfaits en oncologie.
Emglev Therapeutics a été acquise par Valerio Therapeutics en septembre 2024, dont elle est désormais une filiale sous le nom de Valour Bio.
France
Île-de-France
Biotech
Cell & Gene therapy
Biotech - Lead optimization
Emglev Therapeutics
Développe, produit et commercialise des tests de diagnostic innovants basés sur le séquençage de nouvelle génération pour mieux caractériser les lymphomes non hodgkiniens et les sarcomes. Ces tests brevetés offrent des diagnostics rapides et fiables sans nécessiter d’équipement supplémentaire, facilitant leur adoption en routine clinique et optimisant la prise en charge des patients.
France
Normandie
Medtech
DM/DiV
Medtech – Market
Genexpath
Start-up qui crée une plateforme SaaS utilisant le traitement du langage naturel (NLP) et l'apprentissage automatique (ML) afin d'automatiser la collecte et l'utilisation des données non structurées pertinentes en oncologie. Gimli a été rachetée en novembre 2024 par Resilience.
France
Île-de-France
Medtech
e-health
Medtech - Development
GIMLI
Développe un test diagnostique in vitro basé sur le microbiome, marqué CE, pour prédire la réponse aux inhibiteurs de points de contrôle immunitaire.
France
Île-de-France
Medtech
DM/DiV
Medtech - Development
GMT Science
Met au point une technologie d’imagerie médicale de nouvelle génération basée sur l’IRM QUTE-CE, qui fournit des biomarqueurs vasculaires en haute résolution. Cette approche non invasive permet d’évaluer avec précision la structure et la fonction des petits vaisseaux sanguins dans tout le corps, offrant aux cliniciens et chercheurs de nouveaux outils pour la détection précoce et la caractérisation des maladies complexes, notamment le cancer.
USA
Florida
Medtech
DM
Medtech - Development
Imaginostics
Développe PT-112, un agent anti-cancéreux innovant induisant la mort cellulaire immunogène. Ciblant la biogenèse des ribosomes, ce candidat médicament favorise une réponse immunitaire anti-tumorale en activant les lymphocytes T cytotoxiques. PT-112 a montré des résultats prometteurs en combinant un traitement direct de la tumeur avec une stimulation de l’immunité anti-cancéreuse, ouvrant la voie à des solutions thérapeutiques novatrices contre les cancers solides et hématologiques.
USA
New York
Biotech
Targeted therapy
Biotech - Phase 2
Promontory Therapeutics
Develops miniaturized microrobots for neurosurgery, enabling biopsies, treatment delivery, and post-operative monitoring in hard-to-reach areas of the body. Thanks to advanced robotics and artificial intelligence technologies, these microrobots offer increased precision and adapt to various medical applications for more effective and less invasive treatments.
France
Île-de-France
Medtech
DM
Medtech - Development
Lauréat
EIC
Robeauté
They were accompanied
bottom of page